Synairgen plc Grant of Options (9515A)

TIDMSNG

RNS Number : 9515A

Synairgen plc

07 June 2021

Press Release

Synairgen plc

('Synairgen' or the 'Company')

Grant of options

Southampton, UK - 7 June 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 4 June 2021 the Board of Synairgen granted options ('Options') over 831,725 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.42 per cent. of the Company's issued share capital.

Following this grant, Synairgen has 9,503,004 options in issue, representing 4.75 per cent. of the Company's issued share capital.

Included in the number of Options granted on 4 June 2021, the following Options were issued to directors:

 
 Director           Options Issued 
 Richard Marsden           135,626 
                   --------------- 
 Dr. Phillip 
  Monk                      97,953 
                   --------------- 
 John Ward                 105,487 
                   --------------- 
 

Following the issue of the Options, the interests of the directors of the Company at

4 June 2021 are as follows:

 
                                                                        Percentage 
                                                                           holding 
                                                                          of fully 
                                        Ordinary                           diluted 
 Director              Total options      shares   Total interest    share capital 
 Richard Marsden           2,817,576     754,667        3,572,243            1.71% 
                      --------------  ----------  ---------------  --------------- 
 Dr. Phillip Monk          2,046,535     244,600        2,291,135            1.09% 
                      --------------  ----------  ---------------  --------------- 
 John Ward                 2,262,106     514,907        2,777,013            1.33% 
                      --------------  ----------  ---------------  --------------- 
 Simon Shaw                        -   1,531,239        1,531,239            0.73% 
                      --------------  ----------  ---------------  --------------- 
 Iain Buchanan                     -     112,741          112,741            0.05% 
                      --------------  ----------  ---------------  --------------- 
 Dr. Bruce Campbell                -     322,830          322,830            0.15% 
                      --------------  ----------  ---------------  --------------- 
 Prof. Sir Stephen 
  Holgate                          -     886,931          886,931            0.42% 
                      --------------  ----------  ---------------  --------------- 
 

In addition, Jody Brookes, Richard Hennings and Victoria Tear, persons disclosing managerial responsibilities, were granted 62,460, 242,568 and 49,968 Options respectively on the same terms as above. The balance of the Options were granted to a number of employees.

The Options are issued under the Company's Long Term Incentive Plans and are exercisable up to 3 June 2031, subject to the achievement of appropriate performance criteria.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Jessica Hodgson, Carina Jurs

[e-mail]

Tel: [phone]

MK Strategies, LLC (US Media Relations)

Mary Conway

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.

Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Richard Marsden 
2.  Reason for notification 
a)  Position / status                            Chief Executive Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                       135,626 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      4 June 2021 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Dr Phillip Monk 
2.  Reason for notification 
a)  Position / status                            Chief Scientific Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                       97,953 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      4 June 2021 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         John Ward 
2.  Reason for notification 
a)  Position / status                            Chief Financial Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
     Identification code 
 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        105,487 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      4 June 2021 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Jody Brookes 
2.  Reason for notification 
a)  Position / status                            Head of Clinical Operations 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        62,460 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      4 June 2021 
f)  Place of the transaction                     Outside a trading venue 
 
 

1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Victoria Tear 
2.  Reason for notification 
a)  Position / status                            Head of Laboratories 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        49,968 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      4 June 2021 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Richard Hennings 
2.  Reason for notification 
a)  Position / status                            Chief Commercial Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        242,568 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      4 June 2021 
f)  Place of the transaction                     Outside a trading venue 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFMBTMTIMBMB

(END) Dow Jones Newswires

June 07, 2021 02:00 ET (06:00 GMT)